Stocks Health care ENTA
NASDAQ · Health careEnanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals Inc brought in $65.3M of revenue over the twelve months to June 30, 2026, up 0.7% from a year earlier. It posted a net loss of $63.2M. In fiscal 2025 capital spending exceeded operating cash flow by $32.2M. At June 30, 2026 it held $33.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Enanta Pharmaceuticals Inc
- Net worth
- Enanta Pharmaceuticals Inc has a market value (market cap) of $326.8M at the latest share price, and shareholders' equity of $101.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $65.3M (-3.4% year on year), with a net loss of $81.9M. Over the 12 months to June 30, 2026: revenue $65.3M, net loss $63.2M.
- Cash flow
- In fiscal 2025 operations used $19.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Enanta Pharmaceuticals Inc's next report is expected around November 16, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Enanta Pharmaceuticals Inc does
Enanta Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ENTA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $65.3M | -$81.9M | -$3.84 | -$32.2M |
| 2024 | $67.6M | -$116M | -$5.48 | -$96.7M |
| 2023 | $79.2M | -$133.8M | -$6.38 | -$112.2M |
| 2022 | $86.2M | -$121.8M | -$5.91 | -$86.9M |
| 2021 | $97.1M | -$79M | -$3.92 | -$70.7M |
| 2020 | $122.5M | -$36.2M | -$1.81 | $5.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ENTA ranks in Health care
Latest SEC filings
What Enanta Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026Other event 8-K
- October 28, 2026
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 22% to $14.4M versus the same quarter last year; diluted EPS -$0.67 versus -$0.85.
- August 10, 2026
- July 2, 2026
- June 23, 2026Other event 8-K
- June 18, 2026
Insider trades
What the people running Enanta Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 8, 2026 | Rottinghaus Scott T.Chief Medical Officer | Shares withheld for tax | 1,467 | $19.6K |
| February 12, 2026 | Luly Jay R.President and CEO, Director | Received as pay | 4,800 | - |
| February 12, 2026 | Luly Jay R.President and CEO, Director | Received as pay | 15,200 | - |
| February 12, 2026 | Luly Jay R.President and CEO, Director | Shares withheld for tax | 6,155 | $87.7K |
| February 12, 2026 | Or Yat SunChief Scientific Officer | Received as pay | 1,650 | - |
| February 12, 2026 | Or Yat SunChief Scientific Officer | Received as pay | 5,225 | - |
| February 12, 2026 | Or Yat SunChief Scientific Officer | Shares withheld for tax | 3,413 | $48.6K |
| February 12, 2026 | Rottinghaus Scott T.Chief Medical Officer | Received as pay | 1,650 | - |
Who owns ENTA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive with 1 related filers | 12.1% | November 7, 2025 |
| Dapice Joshua J.13G, passive with 28 related filers | 9.8% | February 5, 2026 |
| Farallon Capital Management, L.L.C.13G, passive with 26 related filers | 8.3% | August 14, 2026 |
| Jay R. Luly, Ph.D.13D, may seek influence | 7.7% | February 14, 2025 |
| BlackRock Portfolio Management LLC13G, passive | 5.4% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 122 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 3,654,920 | new |
| BlackRock, Inc. | 3,244,448 | +140,680 |
| Farallon Capital Management, L.L.C. | 2,418,202 | -453,660 |
| Deep Track Capital, LP | 1,444,167 | -512,700 |
| ADAR1 Capital Management, LLC | 1,344,510 | +1,293,153 |
| Vanguard Capital Management LLC | 1,211,769 | +33,720 |
| Spruce Street Capital LP | 1,088,731 | +156,133 |
| Vanguard Portfolio Management LLC | 1,011,494 | +62,590 |
| Geode Capital Management, LLC | 776,634 | +51,573 |
| Millennium Management LLC | 643,967 | -238,130 |
| State Street Corp | 576,117 | +14,011 |
| Renaissance Technologies LLC | 557,600 | -107,658 |
| Hillsdale Investment Management Inc. | 468,000 | +32,490 |
| Goldman Sachs Group Inc | 464,649 | +199,561 |
| Morgan Stanley | 315,729 | +6,218 |
| Charles Schwab Investment Management Inc | 301,151 | +6,180 |
| Dimensional Fund Advisors LP | 282,682 | +79,430 |
| Northern Trust Corp | 259,696 | +18,728 |
| SummitTX Capital, L.P. | 257,702 | new |
| Aqr Capital Management LLC | 256,870 | -56,287 |
Insiders
8 insiders reported holding 1,374,387 shares in total, about $15.4M at the last price.
| Holder | Shares |
|---|---|
| Luly Jay R.President and CEO, Director | 871,871 |
| Or Yat SunChief Scientific Officer | 374,854 |
| Luu BrendanChief Business Officer | 41,634 |
| Kieffer Tara LynnChief Product Strategy Officer | 33,925 |
| Rottinghaus Scott T.Chief Medical Officer | 23,787 |
| Trout Harry R. IIISee Remarks | 16,348 |
| Capps Kathleen S.See Remarks | 8,377 |
| Kowalsky Matthew PaulChief Legal Officer | 3,591 |
Questions about ENTA
What does Enanta Pharmaceuticals Inc do?
Enanta Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as ENTA. Its shares trade on NASDAQ under the ticker ENTA.
What is Enanta Pharmaceuticals Inc's net worth?
Enanta Pharmaceuticals Inc has a market value (market cap) of $326.8M at the latest share price, and shareholders' equity of $101.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Enanta Pharmaceuticals Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $63.2M on revenue of $65.3M.
How much revenue does Enanta Pharmaceuticals Inc make?
Over the twelve months to June 30, 2026 Enanta Pharmaceuticals Inc reported revenue of $65.3M. That is 0.7% more than a year earlier.
When did Enanta Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 29, 2026.
When is Enanta Pharmaceuticals Inc's next earnings report?
Enanta Pharmaceuticals Inc's next report is expected around November 16, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ENTA with
Follow ENTA
Get an email when Enanta Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Enanta Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.